Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PROCEPT BioRoboticsPRCT +0.59%70 3-Year FCF Growth Rate is 17.50% as of Jun. 2026, which is 237% above its 10-year median of 5.20. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $86.54 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 587 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks worse than 50.94% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 17.50% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 7.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 7 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of PROCEPT BioRobotics was 17.50% per year. The lowest was -26.80% per year. And the median was 5.20% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
PROCEPT BioRobotics 3-Year FCF Growth Rate Related Terms
PRCT vs BVS, IRMD, LMRI: 3-Year FCF Growth Rate Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics 3-Year FCF Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 17.50% mean?
PROCEPT BioRobotics (PRCT) has a 3-Year FCF Growth Rate of 17.50% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for PROCEPT BioRobotics and its competitors. This is 237% above median its historical median of 5.20. According to the industry distribution chart, PROCEPT BioRobotics ranks #299 out of 587 companies in the Medical Devices & Instruments industry, placing it in the top 50.9%.
Is PROCEPT BioRobotics' 3-Year FCF Growth Rate too high?
PROCEPT BioRobotics' current 3-Year FCF Growth Rate of 17.50% is 237% above median its 10-year median of 5.20. The Medical Devices & Instruments industry median 3-Year FCF Growth Rate is 18.00. PROCEPT BioRobotics' value of 17.50% is 2.8% below this industry median. Based on the distribution chart, PROCEPT BioRobotics ranks #299 out of 587 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' 3-Year FCF Growth Rate compare to BVS and IRMD?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #299 out of 587 companies for 3-Year FCF Growth Rate. This places PROCEPT BioRobotics in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 18.00. PROCEPT BioRobotics' value of 17.50% is 2.8% below this benchmark. While the company's 10-year median is 5.20 vs. the industry median of 18.00, PROCEPT BioRobotics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Medical Devices & Instruments company?
The median 3-Year FCF Growth Rate among Medical Devices & Instruments companies is 18.00, based on 587 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROCEPT BioRobotics's current 3-Year FCF Growth Rate of 17.50% is 2.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year FCF Growth Rate is 18.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current 3-Year FCF Growth Rate is 17.50%, which is 237% above median its own 10-year median of 5.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $86.54, compared to a current price of $18.62 — trading 78.5% below its estimated fair value. The current 3-Year FCF Growth Rate is 17.50%, which is 237% above median its 10-year median of 5.20 and 2.8% below the Medical Devices & Instruments industry median of 18.00. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current 3-Year FCF Growth Rate is 17.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of $18.62 is trading 78.5% below its estimated GF Value™ of $86.54.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for PRCT:
3-Year FCF Growth Rate: 17.50% (237% above median its 10-year median of 5.20)
GF Value™: $86.54 vs. price of $18.62 (78.5% below fair value)
Industry Position: 2.8% below the Medical Devices & Instruments median (#299 of 587)
No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a medical device company that develops, manufactures, and sells robotic systems for minimally invasive urologic surgery. Its principal offering is the AquaBeam Robotic System, which uses Aquablation therapy, an image-guided, heat-free waterjet ablation technique, to treat benign prostatic hyperplasia (BPH), a common condition in men. The company also markets the HYDROS Robotic System, a next-generation platform. PROCEPT sells its systems, single-use handpieces, and related consumables primarily to hospitals, ambulatory surgery centers, and urologists. Revenue is generated through system placements and the recurring sale of disposable instruments used in each procedure. The company generates the majority of its revenue in the United States, where it has expanded its installed base and trained physician network, and it also sells in selected international markets. PROCEPT is headquartered in San Jose, California.
70GF Score
Get the complete analysis for PRCT
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRCT has been successfully added to your 
